What Are the Risks for Moderna Shareholders?
Moderna (NASDAQ: MRNA) stock has had an amazing run as the biotech company produced a COVID-19 vaccine with 94% efficacy in under a year. Is it too late to buy shares in Moderna? What are the risks? Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool contributor Taylor Carmichael discuss potential pitfalls with Moderna's stock right now in this Motley Fool Live clip, recorded on Feb. 19.
Source Fool.com


